Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Cash: 2020-2025

Historic Change in Cash for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to $25.7 million.

  • SAB Biotherapeutics' Change in Cash rose 418.82% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.3 million, marking a year-over-year increase of 200.24%. This contributed to the annual value of -$47.7 million for FY2024, which is 214.81% down from last year.
  • Latest data reveals that SAB Biotherapeutics reported Change in Cash of $25.7 million as of Q3 2025, which was up 1,420.87% from -$1.9 million recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Change in Cash peaked at $54.1 million during Q4 2023, and registered a low of -$42.5 million during Q1 2024.
  • Moreover, its 3-year median value for Change in Cash was -$2.0 million (2023), whereas its average is $1.3 million.
  • As far as peak fluctuations go, SAB Biotherapeutics' Change in Cash spiked by 33,841.08% in 2021, and later plummeted by 2,040.72% in 2024.
  • Quarterly analysis of 5 years shows SAB Biotherapeutics' Change in Cash stood at $28.8 million in 2021, then plummeted by 76.68% to $6.7 million in 2022, then surged by 706.30% to $54.1 million in 2023, then tumbled by 100.50% to -$273,209 in 2024, then spiked by 418.82% to $25.7 million in 2025.
  • Its Change in Cash was $25.7 million in Q3 2025, compared to -$1.9 million in Q2 2025 and -$3.3 million in Q1 2025.